Shopping Cart
Remove All
Your shopping cart is currently empty
KBD4466 is a potent oral inhibitor of TLR7 and TLR8, with IC50 values of 0.9 nM and 2.8 nM, respectively. This compound effectively suppresses the inflammatory cytokines IL-6 and IFN-α. KBD4466 has shown to improve disease progression and increase survival rates in the BXSB/MpJ mouse model of systemic lupus erythematosus (SLE). It is suitable for research into autoimmune diseases.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 10 mg | Inquiry | 10-14 weeks | 10-14 weeks | |
| 50 mg | Inquiry | 10-14 weeks | 10-14 weeks |
| Description | KBD4466 is a potent oral inhibitor of TLR7 and TLR8, with IC50 values of 0.9 nM and 2.8 nM, respectively. This compound effectively suppresses the inflammatory cytokines IL-6 and IFN-α. KBD4466 has shown to improve disease progression and increase survival rates in the BXSB/MpJ mouse model of systemic lupus erythematosus (SLE). It is suitable for research into autoimmune diseases. |
| Targets&IC50 | TLR7:0.9 nM |
| In vitro | KBD4466 (Compound 19) inhibits the activity of TLR7 and TLR8. |
| In vivo | KBD4466 (Compound 19) (1 mg/kg, oral, single dose) inhibits the production of IL-6 and IFN-α in a mouse model challenged with R848. Additionally, KBD4466 (10 mg/kg, oral, daily for 14 weeks) alleviates disease symptoms in the BXSB/MpJ mouse model of lupus. |
| Molecular Weight | 468.47 |
| Formula | C24H23F3N6O |
| Cas No. | 3023713-87-0 |
| Smiles | C(F)(F)(F)[C@@]12[C@@](C1)(CN(C2)C=3C4=C(C(C#N)=CC3)N=CC=C4)C=5OC(=NN5)C6CCN(C)CC6 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.